文献速递间质性肺疾病

特发性肺纤维化对社区队列患者长期医疗资源利用的影响

Impact of Idiopathic Pulmonary Fibrosis on Longitudinal Health-care Utilization in a Community-Based Cohort of Patients.
PubMed 文献 · Chest · 2020-07-24

该研究基于Kaiser Permanente北加州电子健康记录(2000-2015),识别691例 incident IPF 患者并与3452例匹配对照比较,评估诊断前后5年的医疗资源利用(HRU)。结果显示IPF患者诊断前后各诊断操作、住院及门诊利用率均显著高于对照,且诊断前至少1年即加速上升并持续5年。

要点

  • IPF患者诊断前后5年内住院和门诊利用率均显著高于匹配对照。
  • 胸部CT、6分钟步行试验和肺功能检查的调整后相对风险在诊断前后均显著升高。
  • 诊断前已使用免疫抑制和IPF特异性治疗,且诊断前后糖皮质激素使用率高。

核心结论

  • IPF患者相比匹配对照的医疗资源利用显著增加,诊断前至少1年开始加速并在随后5年持续升高。

研究设计与样本

  • 基于Kaiser Permanente北加州电子健康记录(2000-2015)的纵向队列研究,识别691例IPF病例并匹配3452例对照。
  • 采用经病例验证的编码算法识别IPF,按年龄、性别和入组时长匹配对照,评估诊断前后5年HRU年率。
  • 使用泊松广义估计方程估计调整后的病例-对照HRU差异。

主要发现

  • IPF病例诊断前后所有诊断操作的调整率均显著增加(P < .001),包括胸部CT(诊断前RR 80.35;诊断后RR 32.79)、6分钟步行试验(诊断前RR 20.81;诊断后RR 34.49)和肺功能检查(诊断前RR 9.50;诊断后RR 13.24)。
  • 全因住院(诊断前RR 1.42;诊断后RR 2.33)和门诊就诊(诊断前RR 1.22;诊断后RR 1.80)在诊断前(P < .05)和诊断后(P < .001)均显著高于对照。
  • 观察到诊断前使用免疫抑制和IPF特异性治疗,以及诊断前后高比例的糖皮质激素使用。

临床怎么用

  • 临床应关注IPF患者诊断前1年起医疗资源利用的加速上升,优化早期识别与全程管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a rare, chronic lung disease associated with substantial symptom burden, morbidity, and cost. Delivery of high-quality effective care in IPF requires understanding health-care resource utilization (HRU) patterns; however, longitudinal data from real-world populations are limited. RESEARCH QUESTION: This study aimed to define HRU attributable to IPF by evaluating a longitudinal cohort of community patients with IPF compared with matched control subjects. STUDY DESIGN AND METHODS: Incident IPF cases were identified in the Kaiser Permanente Northern California electronic health records (2000-2015) using case-validated code-based algorithms. IPF cases were compared with matched control subjects by age, sex, and length of enrollment. Annual rates of HRU measures were assessed during the 5 years pre- and postdiagnosis. Poisson generalized estimating equations were used to estimate adjusted case-control differences in HRU. IPF treatment trends were assessed before and after the availability of IPF-specific medications. RESULTS: A total of 691 IPF cases were identified and matched with 3,452 control subjects. Adjusted rates of all diagnostic procedures were significantly increased (P < .001) for IPF cases compared with control subjects in both the pre- and postindex periods, including chest CT scans (pre-relative risk [RR], 80.35; post-RR, 32.79), 6-min walk tests (pre-RR, 20.81; post-RR, 34.49), and pulmonary function tests (pre-RR, 9.50; post-RR, 13.24). All-cause hospitalizations (pre-RR, 1.42; post-RR, 2.33) and outpatient visits (pre-RR, 1.22; post-RR, 1.80) were significantly higher among cases compared with control subjects during both the preindex (P < .05) and postindex (P < .001) periods. We observed use of immunosuppressive and IPF-specific therapies prior to diagnosis, and high rates of corticosteroid use before and after diagnosis. INTERPRETATION: This study defines a marked increase in HRU in patients with IPF compared with control subjects, with accelerated use beginning at least 1 year prediagnosis and elevated use sustained over the following 5 years. To our knowledge, this is the first study to evaluate longitudinal medication trends in IPF. Collectively, this information is foundational to advancing IPF care delivery models and supporting clinical decision-making.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Farrand E, Iribarren C, Vittinghoff E, et al. Impact of Idiopathic Pulmonary Fibrosis on Longitudinal Health-care Utilization in a Community-Based Cohort of Patients. Chest. 2020. PMID: 32717266. doi:10.1016/j.chest.2020.07.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。